BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30146365)

  • 21. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
    Baliakas P; Jeromin S; Iskas M; Puiggros A; Plevova K; Nguyen-Khac F; Davis Z; Rigolin GM; Visentin A; Xochelli A; Delgado J; Baran-Marszak F; Stalika E; Abrisqueta P; Durechova K; Papaioannou G; Eclache V; Dimou M; Iliakis T; Collado R; Doubek M; Calasanz MJ; Ruiz-Xiville N; Moreno C; Jarosova M; Leeksma AC; Panayiotidis P; Podgornik H; Cymbalista F; Anagnostopoulos A; Trentin L; Stavroyianni N; Davi F; Ghia P; Kater AP; Cuneo A; Pospisilova S; Espinet B; Athanasiadou A; Oscier D; Haferlach C; Stamatopoulos K;
    Blood; 2019 Mar; 133(11):1205-1216. PubMed ID: 30602617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
    He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
    Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
    Pollyea DA; Pratz KW; Wei AH; Pullarkat V; Jonas BA; Recher C; Babu S; Schuh AC; Dail M; Sun Y; Potluri J; Chyla B; DiNardo CD
    Clin Cancer Res; 2022 Dec; 28(24):5272-5279. PubMed ID: 36007102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
    Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
    Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
    Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
    Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.
    Sarkozy C; Terré C; Jardin F; Radford I; Roche-Lestienne C; Penther D; Bastard C; Rigaudeau S; Pilorge S; Morschhauser F; Bouscary D; Delarue R; Farhat H; Rousselot P; Hermine O; Tilly H; Chevret S; Castaigne S
    Genes Chromosomes Cancer; 2014 Jan; 53(1):106-16. PubMed ID: 24249260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.
    Nazha A; Kantarjian HM; Bhatt VR; Nogueras-Gonzalez G; Cortes JE; Kadia T; Garcia-Manero G; Abruzzo L; Daver N; Pemmaraju N; Quintas-Cardama A; Ravandi F; Keating M; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):163-71. PubMed ID: 24461514
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Ferrero S; Rossi D; Rinaldi A; Bruscaggin A; Spina V; Eskelund CW; Evangelista A; Moia R; Kwee I; Dahl C; Di Rocco A; Stefoni V; Diop F; Favini C; Ghione P; Mahmoud AM; Schipani M; Kolstad A; Barbero D; Novero D; Paulli M; Zamò A; Jerkeman M; da Silva MG; Santoro A; Molinari A; Ferreri A; Grønbæk K; Piccin A; Cortelazzo S; Bertoni F; Ladetto M; Gaidano G
    Haematologica; 2020 Jun; 105(6):1604-1612. PubMed ID: 31537689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
    Ou J; Xu X; Deng S; Liang H; Cai Z; Li J; Huang Z; Tang B; Wang Z; Zhou Y; Liu X; Liu Q; Zhou H
    Leuk Lymphoma; 2024 Feb; 65(2):219-227. PubMed ID: 37938093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients.
    Miao Y; Lin P; Saksena A; Xu J; Wang M; Romaguera J; Yin CC; Medeiros LJ; Li S
    Am J Surg Pathol; 2019 Aug; 43(8):1052-1060. PubMed ID: 31045891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
    Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
    J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
    Blakemore SJ; Clifford R; Parker H; Antoniou P; Stec-Dziedzic E; Larrayoz M; Davis Z; Kadalyayil L; Colins A; Robbe P; Vavoulis D; Forster J; Carr L; Morilla R; Else M; Bryant D; McCarthy H; Walewska RJ; Steele AJ; Chan J; Speight G; Stankovic T; Cragg MS; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Schuh A; Strefford JC
    Leukemia; 2020 Jul; 34(7):1760-1774. PubMed ID: 32015491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and Prognosis of Chemotherapy Regimen Containing BTK Inhibitor in Treatment of Recurrent/Refractory Mantle Cell Lymphoma].
    Chen H; Liu XY; Chang Y; Chen ZQ; Li WQ; Zhang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):125-131. PubMed ID: 38387910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
    Rücker FG; Russ AC; Cocciardi S; Kett H; Schlenk RF; Botzenhardt U; Langer C; Krauter J; Fröhling S; Schlegelberger B; Ganser A; Lichter P; Zenz T; Döhner H; Döhner K; Bullinger L
    Leukemia; 2013 Feb; 27(2):353-61. PubMed ID: 22810507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
    Short NJ; Montalban-Bravo G; Hwang H; Ning J; Franquiz MJ; Kanagal-Shamanna R; Patel KP; DiNardo CD; Ravandi F; Garcia-Manero G; Takahashi K; Konopleva M; Daver N; Issa GC; Andreeff M; Kantarjian H; Kadia TM
    Blood Adv; 2020 Nov; 4(22):5681-5689. PubMed ID: 33211826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.
    Holte H; Beiske K; Boyle M; Trøen G; Blaker YN; Myklebust J; Kvaløy S; Rosenwald A; Lingjaerde OC; Rimsza LM; Smeland EB; Scott DW; Kolstad A
    Br J Haematol; 2018 Oct; 183(2):225-234. PubMed ID: 30080252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.
    Kruzova L; Schneiderova P; Holzerova M; Vatolikova M; Divoka M; Turcsanyi P; Urbanova R; Kudelka M; Radvansky M; Kriegova E; Papajik T; Urbankova H
    Leuk Res; 2019 Oct; 85():106218. PubMed ID: 31476701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.